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adenocarcinomaAbstract The growth inhibition of stictic acid, a secondary metabolite isolated from the lichen
Lobaria pulmonaria (L.) Hoffm. (Lobariaceae), was evaluated in vitro on three human cell lines
for the first time. The cell lines HT-29 and MCF-7 were utilized for measuring the activity of stictic
acid against cancer cells, while the cell line MRC-5 was selected for estimation of its effect on nor-
mal cells. The results suggest a moderate anticancer activity (IC50 value for the cell line HT-29 was
29.29 lg/ml) and a low growth inhibition on nonmalignant cells (IC50 value for the cell line MRC-5
was 2478.40 lg/ml) of stictic acid. This natural product can be considered as a promising lead com-
pound for the design of novel human colon adenocarcinoma drugs.
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Large numbers of different lichen substances can be generated
from a limited set of monoaromatic units. Metabolites, which
arise via phenolic coupling (Geissman and Crout, 1969) and
form a substantial fraction of the chemical diversity of lichens,including p- or m-depsides and depsidones, consist of multiple
phenolic units. Products of phenolic coupling can be modified
by decarboxylation, halogenation, methylation, or esterifica-
tion with short- and long-chain fatty acids. The polyketide bio-
synthetic pathway appears to be responsible (in whole or in
part) for most of the classes of lichen compounds.
Their growth inhibition has been studied for more than
three decades (Kupchan and Kopperman, 1975; Takai et al.,
1979). However, the available sources of data are scarce. Since
most studies have employed lichen extracts instead of chemi-
cally well defined compounds, only a small group of lichen
compounds is tested (Ren et al., 2009; Zeytinoglu et al.,
2008). On the other hand, the limited number of cancer cell
lines has been utilized.
The most common colon cancer cell type is adenocarcinoma
which accounts for 95% of cases. Other, rarer types include
Figure 1 Stictic acid.
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malignant epithelial tumor, originating from glandular epithe-
lium of the colorectal mucosa. It invades the wall, infiltrating
the muscularis mucosae, the submucosa and thence the muscu-
laris propria (Danciu, 2010). Chemotherapy drugs may include
combinations of agents including fluorouracil, capecitabine,
UFT, leucovorin, irinotecan, or oxaliplatin, but such treatment
can cause several side effects. Therefore, it is important to search
for new drugs belonging to different structural classes compared
to the agents in clinical use.
As part of the ongoing project on natural products of evo-
lutionary lower organisms (Pejin et al., 2008, 2012a,b; 2013) a
growth inhibition screening of stictic acid, an isolated b-Orci-
nol depsidone from the lichen Lobaria pulmonaria (L.) Hoffm.
(Lobariaceae), has been performed.
2. Experimental
2.1. General
1H- and 13C NMR spectra were recorded at the NMR Service
of the Institute for Biomolecular Chemistry of National Coun-
cil Research of Italy (CNR-ICB) on a Bruker Avance-400
spectrometer operating 400 and 100 MHz, respectively, using
an inverse probe fitted with a gradient along the Z-axis, in
CDCl3, using the solvent signal as an internal standard.
Thin-layer chromatography was carried out on pre-coated sil-
ica gel 60 F254 (0.25 mm, Merck, Darmstadt, Germany).
LRMS and HRMS were recorded on a JEOL JMS D-300
and an AEI MS-50, respectively.
2.2. Plant material
The lichen L. pulmonaria (L.) Hoffm. (Lobariaceae) was col-
lected from Fagus sylvatica on the mountain Zelengora (Bos-
nia and Herzegovina) in July 2009. Voucher specimen has
been deposited in the Herbarium of the Institute of Botany,
University of Belgrade, Serbia (BEOU 5997).
2.3. Extraction and isolation
Before extraction the lichen was carefully inspected for con-
taminants. Air-dried parts of L. pulmonaria (70 g) were ground
and extracted three times with CHCl3, CHCl3-MeOH 1:1,
MeOH, and MeOH-H2O 1:1, respectively, (500 mL each) at
room temperature, for up to 1 day each, with the extracts
pooled and then evaporated in vacuo. The dried CHCl3-
MeOH (1:1) extract (5.81 g) was dissolved in H2O (50 mL)
and partitioned sequentially with CHCl3 (3 · 50 mL) and n-
BuOH (3 · 50 mL). The crude insoluble colored residue
(0.46 g), obtained after the partition, was classified as fraction
rich in epsilons, by means of its spectroscopic data and typical
chromatographic profile. In order to further characterize the
residue, it was chromatographed on Sephadex LH-20 column
(20 mg) and eluted with the system of CH2Cl2=MeOH 1:1
to yield stictic acid (5 mg, 0.0071% of dry weight).
Stictic acid (Fig. 1): 1H NMR (DMSO-d6, 200 MHz) d
10.44 (1H, s, H-9), 7.10 (1H, s, H-5), 6.70 (1H, s, H-80), 3.92
(3H, s, 0CH3-4), 2.50 (3H, s, H-8), 2.19 (3H, s, H-9
0); 13C
NMR (DMSO-d6, 50 MHz) d 186.7 (CHO, C-9), 167.1
(COO, C-70), 163.2 (C, C-4), 162.4 (C, C-2), 151.2 (C, C-20),150.88 (C, C-6), 147.9 (C, C-40), 137.4 (C, C-60), 135.8 (C, C-
50), 120.5 (C, C-30), 114.4 (C, C-3), 109.8 (C, C-10), 113.1 (C,
C-1), 112.8 (CH, C-5), 95.5 (C, C-80), 56.8 (C, 0CH3-4), 21.6
(CH3, C-8), 9.6 (CH3, C-9
0). ESIMS m/z 385 [M-H]+ (calcd.
for C19H13O9, 385.0559).
2.4. Cell lines
The cell lines used in the study were MCF-7 (human breast
adenocarcinoma, ATCC HTB22), HT-29 (human colon ade-
nocarcinoma, ATCC HTB38) and MRC-5 (human fetal lung
fibroblasts, ATCC CCL 171). The cells were grown in Dul-
becco’s modified Eagle’s medium (DMEM) with 4.5% of glu-
cose, supplemented with 10% of fetal calf serum (FCS,
NIVNS) and antibiotics: 100 IU/cm3 of penicillin and
100 lg/cm3 of streptomycin (ICN Galenika). The cells were
sub-cultured twice a week and a single cell suspension was ob-
tained using 0.25% trypsin in EDTA (Serva). All cell lines
were cultured in flasks (Sarstedt, 25 cm2) at 37 C in 100%
humidity atmosphere and 5% of CO2. Exponentially growing
cells were used throughout the assays. The cell density (number
of cells per unit volume) and percentage of viable cells were
performed as previously described (Bogdanovic´ et al., 1994).
Viability of cells used in the assay was over 95%.
2.5. MTT assay
Growth inhibition was evaluated by tetrazolium colorimetric
MTT assay (SIGMA). Cells were plated into 96-well microtiter
plates (Costar) in a volume of 90 ll per well, in the complete
medium at an optimal seeding density of 5 · 103 cells per well
to assure a logarithmic growth rate throughout the assay period.
Tested substance at a concentration ranging from 108 lg to
104 M was added to all wells except to the control ones. Plates
were incubated at 37 C for 48 h. Three hours before the end of
incubation period 10 ll of MTT solution (5 mg/ml) was added
to all wells and plates were incubated for 3 h at 37 C, after
which medium andMTT were removed by suction. The forma-
zan product was then solubilized in 100 ll of 0.04 MHCl of iso-
PropOH. After a few minutes at room temperature, the plates
were read on a spectrophotometer plate reader (Multiscan
MCC340, Labsystems) at 540/690 nm. The wells without cells
containing complete medium and MTT only acted as blank.
Growth inhibition was expressed as a percent and calculated
according to the formula: % C= 1  (ODtest/ODcontrol) · 100.
Figure 2 The effect of stictic acid on the growth of human cell
lines. Human colon adenocarcinoma HT-29, breast adenocarci-
noma MCF-7, or human normal fetal lung fibroblast MRC-5 were
cultured for 48 h in the absence or presence of different doses of
stictic acid as indicated and cell growth was measured using
colorimetric MTT assay. Results are presented as % of death cells
compared to untreated cells (100% viable).
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Two independent experiments were set out with quadruplicate
wells for each concentration of the compound. IC50 value de-
fines the dose of compound that inhibits cell growth by 50%.
The IC50 of the extract was determined by Median effect anal-
ysis (Mosmann, 1983).
3. Results and discussion
High-resolution mass spectrometry established the molecular
formula of known depsidone stictic acid (C19H1409, Fig. 1).
The structure followed from1-D and 2-DNMRspectra. A com-
bination of 2-D NMR experiments (COSY, NOESY, HSQC
and HMBC) allowed assigning of all signals in the 1H- and
13C-NMRspectra. The spectral data are in good agreement with
those previously reported in the literature (Elix et al., 1996).
The anticarcinogenic activity of stictic acid was evaluated
by MTT assay against two human cancer cell lines (HT-29
and MCF-7) and one human normal cell line (MRC-5) for
the first time. As depicted in Fig. 2, HT-29 human colon ade-
nocarcinoma cells were found to be the most sensitive to stictic
acid (IC50 value 29.29 lg/ml); compared to MCF-7 human
breast adenocarcinoma, the tested compound was 689-fold
more sensitive to the cell line HT-29. On the other hand, stictic
acid showed a low growth inhibition on the nonmalignant cells
(IC50 value for the cell line MRC-5 was 2478.40 lg/ml).
In comparison, the lichen substances such as atranorin,
gyrophoric acid, parietin and usnic acid were less active toward
the cell line HT-29 (IC50 values >200,>200,>200 and
99.70 ± 8.40 lg/ml, respectively) after 72 h exposition
(Bacˇkorova´ et al., 2011). Furthermore, through investigation
of the mechanisms of cytotoxicity of these four secondary
metabolites, the same research group found that usnic acid
and atranorin were more effective anticancer compounds on
HT-29 cells compared to parietin and gyrophoric acid (Bacˇk-
orova´ et al., 2012). However, our results indicate that stictic
acid, a widely distributed depsidone among lichens, can be
considered as a more promising lead compound for the design
of novel human colon adenocarcinoma drugs in relation tousnic acid and atranorin. Hence, structure–activity relation-
ship (SAR) of stictic acid and its derivatives is worthy of
investigation.
4. Conclusions
In summary, it may be concluded that stictic acid is more effec-
tive anticancer compound on the malignant HT-29 cell line
than usnic acid, the most extensively studied lichen metabolite
till date (Mitrovic´ et al., 2011). Among the rest, further work
should be focused on the molecular mechanism by which this
depsidone induces the aforementioned growth inhibition. Ta-
ken together, it seems reasonable to assume that stictic acid
may inspire new drugs for the treatment of colorectal tumors
which are still among the most common and lethal types of
cancer worldwide (Botteri et al., 2008).Acknowledgement
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